Shots:

• Sanofi will sponsor the clinical trials while MSD will provide KEYTRUDA. Additionally- Sanofi is separately evaluating the activity of THOR-707 in combination with other anti-PD-1 antibodies- including Libtayo (cemiplimab-rwlc) and with anti-EGFR and anti-CD38 antibodies for various types of cancer tumors
• In preclinical studies- THOR-707 demonstrated the ability to induce the expansion of CD8+T-cells resulting in anti-tumor effects both as a single agent as well as in combination with an anti-PD1 mAb
• THOR-707 is currently being evaluated by Sanofi in an ongoing P-I dose escalation and expansion trial assessing THOR-707 and determining its recommended P-II dose alone and in combination with anti-PD-1 and anti-EGFR antibodies

  Ref: Sanofi | Image: Sanofi